Skip Navigation



Journal of Tropical Pediatrics Advance Access published online on May 25, 2005
Journal of Tropical Pediatrics, doi:10.1093/tropej/fmh097
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
51/4/200    most recent
fmh097v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Akinsulie, A. O.
Right arrow Articles by Whyte, C. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akinsulie, A. O.
Right arrow Articles by Whyte, C. O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press; all rights reserved

Original Papers

Clinical Evaluation of Extract of Cajanus cajan (Ciklavit®) in Sickle Cell Anaemia

A. O. Akinsulie 1, E. O. Temiye 1*, A. S. Akanmu 2, F. E. A. Lesi 1, and C. O. Whyte 1

1 Department of Paediatrics, College of Medicine of University of Lagos (CMUL), Nigeria
2 Department of Haematology and Blood Transfusion, College of Medicine of University of Lagos (CMUL), Nigeria

* To whom correspondence should be addressed.
E. O. Temiye, E-mail: edatemiye2000{at}yahoo.co.uk


  Abstract

The major pathology in sickle cell anaemia (SCA) is sickling of red cells due to the precipitation of reduced haemoglobin. We report our experience with extract of Cajanus cajan as a possible antisickling agent by determining changes, if any, in clinical and laboratory features of the disease in patients given the extract in a single-blind placebo-controlled study. One hundred patients with steady-state SCA were randomized into treatment and placebo arms. The extract/placebo were administered twice daily to the subjects. Weight, hepatosplenomegaly, blood levels of biliurubin, urea, creatinine, and packed cell volume (PCV) were monitored over a 6-month period. Recall episodes of pain 6 months before enrolment were compared with episodes of pains recorded during the treatment period. Twenty-six cases (55.3 per cent) had hepatomegaly on enrolment. This significantly reduced to 33.3 per cent at 6 months (p = 0.03); but increased in the placebo arm (p > 0.05). The total number of recall painful episodes in cases was 207 (mean 4.4 ± 10.3 (SD), range 0-60) and fell to 191 (mean 4.2 ± 4.4 (SD), range 0-16); p = 0.03. Episodes of pain increased from 109 in controls (mean 2.6 ± 5.0 (SD), range 0-26) to 164 (mean 3.9 ± 4.3 (SD), range 0-22); p = 0.01. Mean PCV in the cases showed no appreciable changes (p = 0.1) but there was a significant increase in the controls (p = 0.02). In conclusion, the extract may cause a reduction of painful crises and may ameliorate the adverse effects of sickle cell anaemia on the liver. The mechanism of action remains to be determined.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

Extract of Cajanus Cajan for reducing painful crises in Sickle cell Anaemia
Ayokunle . T. Abegunde
Journal of Tropical Pediatrics, 18 Aug 2005 [Full text]

Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.